Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms
Conditions
Interventions
Intervention1: Tadalafil: Combination Therapy of Silodosin 8mg plus Tadalafil 5mg once daily at night time
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Control Intervention1: Silodosin: Silodosin 8
Sponsors
Dr Pulluru Bala Susheeth Kumar
Eligibility
Inclusion criteria
Inclusion criteria: IPSS Score greater than 8 qmax less tham 10ml per sec PVR less than 150ml per sec
Exclusion criteria
Exclusion criteria: 1 Presence of prostate cancer or bladder carcinoma 2 Associated Urethral Stricture 3 Complicated BPH (patients with refractory urinary retention, renal insufficiency, recurrent urinary tract infections, recurrent bladder stones or gross hematuria secondary to BPH) 4 Insufficient renal function (serum creatinine concentration greater than 2 mgper dL) 5 Cardiac patients 6 Patients with history of hypersensitivity to these drugs 7 Patients who are not able to understand IPSS Questionnaire
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study analyse and compare Efficacy of Silodosin versus silodosin with Tadalafil for Lower Urinary tract symptoms in Benign Prostatic HyperplasiaTimepoint: 2 weeks 1 month 2 months 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| nilTimepoint: nil | — |
Countries
India
Contacts
Public ContactDr Pulluru Bala Susheeth Kumar
Dr Pinnamaneni Siddhartha Institute Of Medical Sciences And Research Foundation
Outcome results
None listed